BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 30295249)

  • 1. [Clinicopathological Characteristics and Prognosis Analysis of the Patients with Plasmablastic Lymphoma].
    Feng J; Xu L; Dong HJ; Zhang N; Bai QX; Liang R; Shu MM; Yang L; Chen XQ; Gu HT; Gao GX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1350-1354. PubMed ID: 30295249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmablastic lymphoma - single centre experience with infusional EPOCH chemotherapy.
    Jayachandran PK; Rajan AK; Karunakaran P; Mehra N; Selvarajan G; Kesana S; Dhanushkodi M; Radhakrishnan V; Sagar TG
    Leuk Res; 2020 Aug; 95():106391. PubMed ID: 32559556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical features and outcomes: analysis of 9 cases of HIV-negtive plasmablastic lymphoma].
    Gui L; He XH; Liu P; Yang JL; Qin Y; Zhou SY; Yang S; Zhang CG; Shi YK
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):762-767. PubMed ID: 27719718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    Koizumi Y; Uehira T; Ota Y; Ogawa Y; Yajima K; Tanuma J; Yotsumoto M; Hagiwara S; Ikegaya S; Watanabe D; Minamiguchi H; Hodohara K; Murotani K; Mikamo H; Wada H; Ajisawa A; Shirasaka T; Nagai H; Kodama Y; Hishima T; Mochizuki M; Katano H; Okada S
    Int J Hematol; 2016 Dec; 104(6):669-681. PubMed ID: 27604616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients.
    Mai B; Wang W; Lin M; Hu S; Wang XI; Chen L; Wahed A; Nguyen A; Ma HY; Medeiros LJ; Hu Z
    AIDS; 2020 Oct; 34(12):1735-1743. PubMed ID: 32889849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa.
    Rapiti N; Peer N; Abdelatif N; Rapiti P; Moosa Y
    HIV Med; 2022 Sep; 23(8):837-848. PubMed ID: 35229978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Emerging Treatment Options of Plasmablastic Lymphoma: Analysis of 173 Individual Patient Outcomes.
    Makady NF; Ramzy D; Ghaly R; Abdel-Malek RR; Shohdy KS
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):e255-e263. PubMed ID: 33419717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy.
    Castillo JJ; Furman M; Beltrán BE; Bibas M; Bower M; Chen W; Díez-Martín JL; Liu JJ; Miranda RN; Montoto S; Nanaji NM; Navarro JT; Seegmiller AC; Vose JM
    Cancer; 2012 Nov; 118(21):5270-7. PubMed ID: 22510767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
    Pinnix CC; Shah JJ; Chuang H; Costelloe CM; Medeiros LJ; Wogan CF; Reed V; Smith GL; Milgrom S; Patel K; Huo J; Turturro F; Romaguera J; Fayad L; Oki Y; Fanale MA; Westin J; Nastoupil L; Hagemeister FB; Rodriguez A; Qazilbash M; Shah N; Bashir Q; Ahmed S; Nieto Y; Hosing C; Rohren E; Dabaja B
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):122-8. PubMed ID: 26795083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmablastic lymphoma in HIV patients: Experience at a tertiary care hospital in eastern India.
    Bishnu S; Banerjee S; Bandyopadhyay D; Samui S; Bhattacharya S; Bose D
    Indian J Cancer; 2015; 52(4):563-7. PubMed ID: 26960478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human immunodeficiency virus-negative plasmablastic lymphoma: a comprehensive analysis of 114 cases.
    Liu M; Liu B; Liu B; Wang Q; Ding L; Xia C; Dong L
    Oncol Rep; 2015 Apr; 33(4):1615-20. PubMed ID: 25695332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in chemotherapy-treated patients with HIV-associated Plasmablastic lymphoma.
    Castillo JJ; Winer ES; Stachurski D; Perez K; Jabbour M; Milani C; Colvin G; Butera JN
    Oncologist; 2010; 15(3):293-9. PubMed ID: 20167839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.
    Evens AM; Kanakry JA; Sehn LH; Kritharis A; Feldman T; Kroll A; Gascoyne RD; Abramson JS; Petrich AM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Adeimy C; Hemminger J; Bartlett NL; Mato A; Caimi PF; Advani RH; Klein AK; Nabhan C; Smith SM; Fabregas JC; Lossos IS; Press OW; Fenske TS; Friedberg JW; Vose JM; Blum KA
    Am J Hematol; 2015 Sep; 90(9):778-83. PubMed ID: 26044261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
    Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
    Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and treatment strategies for early-stage primary gastric diffuse large B-cell lymphoma].
    Qin Y; Liu P; Yang JL; Jin J; He XH; Wang WH; Fang H; Zhou SY; Zhou LQ; Song YW; Shi YK
    Zhonghua Yi Xue Za Zhi; 2018 Jun; 98(24):1945-1950. PubMed ID: 29996288
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib- and Lenalidomide-Based Treatment of Refractory Plasmablastic Lymphoma.
    Ando K; Imaizumi Y; Kobayashi Y; Niino D; Hourai M; Sato S; Sawayama Y; Hata T; Ohshima K; Miyazaki Y
    Oncol Res Treat; 2020; 43(3):112-116. PubMed ID: 31842017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.
    Arora N; Gupta A; Sadeghi N
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 28993364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bleomycin, epidoxorubicin, cyclophosphamide, vincristine and prednisone (BACOP) in patients with follicular non-Hodgkin's lymphoma: results of a prospective, multicenter study of the Gruppo Italiano Per Lo Studio Dei Linfomi (GISL).
    Lombardo M; Morabito F; Merli F; Molica S; Cavanna L; Sacchi S; Broglia C; Angrilli F; Ilariucci F; Stelitano C; Luisi D; Bertè R; Luminari S; Federico M; Brugiatelli M;
    Leuk Lymphoma; 2002 Sep; 43(9):1795-801. PubMed ID: 12685834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.